Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity

Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), which was approved by the National Medical Products Administration (NMPA) of China in 2018 for the third-line treatment of non-small cell lung cancer (NSCLC). Here, for the first time, the longitudinal pharma...

Full description

Bibliographic Details
Main Authors: Ting Hu, Zhuoling An, Yongkun Sun, Xunqiang Wang, Ping Du, Pengfei Li, Yihebali Chi, Lihong Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
pharmacometabonomics
anlotinib
phenotype
efficacy
toxicity
ultra-high performance liquid chromatography-tandem mass spectrometry
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.548300/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.548300/full

Similar Items